Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14.
doi: 10.3324/haematol.2023.284109.
Online ahead of print.
1 La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo, Italy; Tumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
2 Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
3 Universitè Paris Citè; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
4 CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac.
5 Univ. Grenoble Alpes. Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309). University Hospital, Molecular Biology and Hematology departments, Grenoble.
6 Ematologia AOU delle Marche, Ancona.
7 Department of Hematology, Centre Henri Becquerel, Rouen.
8 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo.
9 Fondazione Italiana Linfomi ETS, Modena.
10 Azienda Unità Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia.
11 Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese.
12 Nantes University Hospital and CRC2 NA, Nantes.
13 UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria.
14 Universitè Paris Citè.
15 Dipartimento di Medicina e Chirurgia, Università di Parma, AOU di Parma.
16 Department of Hematology, Ravenna hospital, Ravenna.
17 Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma.
18 Laboratoire d'Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
19 Service d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
20 Tumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
21 Oncohematology Unit, University of Perugia, Azienda Ospedaliera S.Maria, Terni.
22 Ematologia Istituto Romagnolo Per Lo studio dei Tumori Dino Amadori, Meldola.
23 Ospedale Oncologico A. Businco, Cagliari.
24 U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo.
25 CHIMOMO dept. University of Modena and Reggio Emilia.
26 La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo.
27 University of Eastern Piedmont Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria.
28 IOSI, Oncology Institute of Southern Switzerland and IOR: Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona, Switzerland.